|
1
|
Xie J, Poole EM, Terry KL, Fung TT, Rosner
BA, Willett WC and Tworoger SS: A prospective cohort study of
dietary indices and incidence of epithelial ovarian cancer. J
Ovarian Res. 7:1122014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cella D, Neubauer N, Thomas J, Kutner J
and Seiden MV: The FACIT-AI, a new tool for assessing symptoms
associated with malignant ascites. Gynecol Oncol. 128:187–190.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kipps E, Tan DS and Kaye SB: Meeting the
challenge of ascites in ovarian cancer: New avenues for therapy and
research. Nat Rev Cancer. 13:273–282. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rosenberg SA, Packard BS, Aebersold PM,
Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp
CA, et al: Use of tumor-infiltrating lymphocytes and interleukin-2
in the immunotherapy of patients with metastatic melanoma. A
preliminary report. N Engl J Med. 319:1676–1680. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dudley ME, Wunderlich JR, Yang JC, Sherry
RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE,
Mavroukakis SA, et al: Adoptive cell transfer therapy following
non-myeloablative but lymphodepleting chemotherapy for the
treatment of patients with refractory metastatic melanoma. J Clin
Oncol. 23:2346–2357. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Besser MJ, Shapira-Frommer R, Treves AJ,
Zippel D, Itzhaki O, Hershkovitz L, Levy D, Kubi A, Hovav E,
Chermoshniuk N, et al: Clinical responses in a phase II study using
adoptive transfer of short-term cultured tumor infiltration
lymphocytes in metastatic melanoma patients. Clin Cancer Res.
16:2646–2655. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dudley ME, Yang JC, Sherry R, Hughes MS,
Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, et
al: Adoptive cell therapy for patients with metastatic melanoma:
Evaluation of intensive myeloablative chemoradiation preparative
regimens. J Clin Oncol. 26:5233–5239. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ferrini S, Biassoni R, Moretta A, Bruzzone
M, Nicolin A and Moretta L: Clonal analysis of T lymphocytes
isolated from ovarian carcinoma ascitic fluid. Int J Cancer.
36:337–343. 1985.PubMed/NCBI
|
|
9
|
Freedman RS, Tomasovic B, Templin S,
Atkinson EN, Kudelka A, Edwards CL and Platsoucas CD: Large-scale
expansion in interleukin-2 of tumor-infiltrating lymphocytes from
patients with ovarian carcinoma for adoptive immunotherapy. J
Immunol Methods. 167:145–160. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Aoki Y, Takakuwa K, Kodama S, Tanaka K,
Takahashi M, Tokunaga A and Takahashi T: Use of adoptive transfer
of tumor-infiltrating lymphocytes alone or in combination with
cisplatin-containing chemotherapy in patients with epithelial
ovarian cancer. Cancer Res. 51:1934–1939. 1991.PubMed/NCBI
|
|
11
|
Fujita K, Ikarashi H, Takakuwa K, Kodama
S, Tokunaga A, Takahashi T and Tanaka K: Prolonged disease-free
period in patients with advanced epithelial ovarian cancer after
adoptive transfer of tumor-infiltrating lymphocytes. Clin Cancer
Res. 1:501–507. 1995.PubMed/NCBI
|
|
12
|
Freedman RS and Platsoucas CD:
Immunotherapy for peritoneal ovarian carcinoma metastasis using ex
vivo expanded tumor infiltrating lymphocytes. Cancer Treat Res.
82:115–146. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Han X, Papadopoulos AJ, Ruparelia V,
Devaja O and Raju KS: Tumor lymphocytes in patients with advanced
ovarian cancer: Changes during in vitro culture and implications
for immunotherapy. Gynecol Oncol. 65:391–398. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mantovani A, Allavena P, Sessa C, Bolis G
and Mangioni C: Natural killer activity of lymphoid cells isolated
from human ascitic ovarian tumors. Int J Cancer. 25:573–582. 1980.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ozenci V, Miller AM, Palmborg A, Egevad L,
Jaremko GA, Kälkner KM and Pisa P: Presence and specificity of
tumor associated lymphocytes from ascites fluid in prostate cancer.
Prostate. 65:20–26. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Santin AD, Hermonat PL, Ravaggi A, Bellone
S, Roman JJ, Smith CV, Pecorelli S, Radominska-Pandya A, Cannon MJ
and Parham GP: Phenotypic and functional analysis of
tumor-infiltrating lymphocytes compared with tumor-associated
lymphocytes from ascitic fluid and peripheral blood lymphocytes in
patients with advanced ovarian cancer. Gynecol Obstet Invest.
51:254–261. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wolchok JD, Hoos A, O'Day S, Weber JS,
Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, et al:
Guidelines for the evaluation of immune therapy activity in solid
tumors: Immune-related response criteria. Clin Cancer Res.
15:7412–7420. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang J, Xing SS, Guo SB, Jin W and Zhang
W: Oxidative DNA damage of lymphocytes in peripheral blood and
ascites in cancer patients. Current Oncol. 19:(Suppl 2). eS10–eS14.
2012. View Article : Google Scholar
|
|
19
|
Apiranthitou-Drogari M, Paganin C,
Bernasconi S, Losa G, Maneo A, Colombo N, Mantovani A and Allavena
P: In search of specific cytotoxic T lymphocytes infiltrating or
accompanying human ovarian carcinoma. Cancer Immunol Immunother.
35:289–295. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Melioli G, Ferrari I, Casartelli G and
Ragni N: Lymphocytes isolated from the peritoneal fluid of women
with advanced ovarian carcinoma differ significantly from
autologous peripheral blood lymphocytes. Gynecol Oncol. 48:301–307.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ioannides CG, Platsoucas CD, Rashed S,
Wharton JT, Edwards CL and Freedman RS: Tumor cytolysis by
lymphocytes infiltrating ovarian malignant ascites. Cancer Res.
51:4257–4265. 1991.PubMed/NCBI
|
|
22
|
Ullenhag GJ, Sadeghi AM, Carlsson B,
Ahlström H, Mosavi F, Wagenius G and Tötterman TH: Adoptive T-cell
therapy for malignant melanoma patients with TILs obtained by
ultrasound-guided needle biopsy. Cancer Immunol Immunother.
61:725–732. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ellebaek E, Iversen TZ, Junker N, Donia M,
Engell-Noerregaard L, Met Ö, Hölmich LR, Andersen RS, Hadrup SR,
Andersen MH, et al: Adoptive cell therapy with autologous tumor
infiltrating lymphocytes and low-dose Interleukin-2 in metastatic
melanoma patients. J Transl Med. 10:1692012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hong JJ, Rosenberg SA, Dudley ME, Yang JC,
White DE, Butman JA and Sherry RM: Successful treatment of melanoma
brain metastases with adoptive cell therapy. Clin Cancer Res.
16:4892–4898. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pilon-Thomas S, Kuhn L, Ellwanger S,
Janssen W, Royster E, Marzban S, Kudchadkar R, Zager J, Gibney G,
Sondak VK, et al: Efficacy of adoptive cell transfer of
tumor-infiltrating lymphocytes after lymphopenia induction for
metastatic melanoma. J Immunother. 35:615–620. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Itzhaki O, Hovav E, Ziporen Y, Levy D,
Kubi A, Zikich D, Hershkovitz L, Treves AJ, Shalmon B, Zippel D, et
al: Establishment and large-scale expansion of minimally cultured
‘young’ tumor infiltrating lymphocytes for adoptive transfer
therapy. J Immunother. 34:212–220. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tran KQ, Zhou J, Durflinger KH, Langhan
MM, Shelton TE, Wunderlich JR, Robbins PF, Rosenberg SA and Dudley
ME: Minimally cultured tumor-infiltrating lymphocytes display
optimal characteristics for adoptive cell therapy. J Immunother.
31:742–751. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dudley ME, Gross CA, Langhan MM, Garcia
MR, Sherry RM, Yang JC, Phan GQ, Kammula US, Hughes MS, Citrin DE,
et al: CD8+ enriched ‘young’ tumor infiltrating
lymphocytes can mediate regression of metastatic melanoma. Clin
Cancer Res. 16:6122–6131. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Allavena P, Introna M, Mangioni C and
Mantovani A: Inhibition of natural killer activity by
tumor-associated lymphoid cells from ascites ovarian carcinomas. J
Natl Cancer Inst. 67:319–325. 1981.PubMed/NCBI
|
|
30
|
Suzuki E, Kapoor V, Jassar AS, Kaiser LR
and Albelda SM: Gemcitabine selectively eliminates splenic
Gr-1+/CD11b+ myeloid suppressor cells in
tumor-bearing animals and enhances antitumor immune activity. Clin
Cancer Res. 11:6713–6721. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu WM, Fowler DW, Smith P and Dalgleish
AG: Pre-treatment with chemotherapy can enhance the antigenicity
and immunogenicity of tumours by promoting adaptive immune
responses. Br J Cancer. 102:115–123. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
North RJ: Cyclophosphamide-facilitated
adoptive immunotherapy of an established tumor depends on
elimination of tumor-induced suppressor T cells. J Exp Med.
155:1063–1074. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cheever MA, Greenberg PD and Fefer A:
Specificity of adoptive chemoimmunotherapy of established syngeneic
tumors. J Immunol. 125:711–714. 1980.PubMed/NCBI
|
|
34
|
Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó
L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, et al:
Crizotinib versus chemotherapy in advanced ALK-positive lung
cancer. N Engl J Med. 368:2385–2394. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gattinoni L, Powell DJ Jr, Rosenberg SA
and Restifo NP: Adoptive immunotherapy for cancer: Building on
success. Nat Rev Immunol. 6:383–393. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ballen KK, Colvin G, Dey BR, Porter D,
Westervelt P, Spitzer TR and Quesenberry PJ: Cellular immune
therapy for refractory cancers: Novel therapeutic strategies. Exp
Hematol. 33:1427–1435. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Giuntoli RL II, Webb TJ, Zoso A, Rogers O,
Diaz-Montes TP, Bristow RE and Oelke M: Ovarian cancer-associated
ascites demonstrates altered immune environment: Implications for
antitumor immunity. Anticancer Res. 29:2875–2884. 2009.PubMed/NCBI
|
|
38
|
Leffers N, Gooden MJ, de Jong RA,
Hoogeboom BN, ten Hoor KA, Hollema H, Boezen HM, van der Zee AG,
Daemen T and Nijman HW: Prognostic significance of
tumor-infiltrating T-lymphocytes in primary and metastatic lesions
of advanced stage ovarian cancer. Cancer Immunol Immu. 58:449–459.
2009. View Article : Google Scholar
|
|
39
|
Facciabene A, Motz GT and Coukos G:
T-regulatory cells: Key players in tumor immune escape and
angiogenesis. Cancer Res. 72:2162–2171. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Friedman KM, Prieto PA, Devillier LE,
Gross CA, Yang JC, Wunderlich JR, Rosenberg SA and Dudley ME:
Tumor-specific CD4+ melanoma tumor-infiltrating
lymphocytes. J Immunother. 35:400–408. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Disis ML, Bernhard H and Jaffee EM: Use of
tumour-responsive T cells as cancer treatment. Lancet. 373:673–683.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Pace L, Tempez A, Arnold-Schrauf C,
Lemaitre F, Bousso P, Fetler L, Sparwasser T and Amigorena S:
Regulatory T cells increase the avidity of primary CD8+
T cell responses and promote memory. Science. 338:532–536. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hinrichs CS and Rosenberg SA: Exploiting
the curative potential of adoptive T-cell therapy for cancer.
Immunol Rev. 257:56–71. 2014. View Article : Google Scholar : PubMed/NCBI
|
